Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, September 2014

Sort by: Newest first Oldest first A-Z Z-A

  • The electronic prescription is one of the answers to Health Secretary Jeremy Hunt challenge that the NHS to go paperless by 2018

    Clarity and accuracy of electronic prescriptions questioned Subscription

    1 OCT 2014 16:58 By Maureen O'Sullivan

    Research has highlighted potential pitfalls of using electronic systems for prescribing.

  • Transatlantic trade agreement could harm access to medicines, Oxfam warns Subscription

    1 OCT 2014 12:07

    Oxfam and a coalition of European organisations have repeated their warning that a proposed trade agreement could harm access to medicines.

  • Statins linked to increase risk of diabetes and weight gain, research says

    Statin target linked to increased risk of diabetes and weight gain Subscription

    1 OCT 2014 11:52

    Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase is partly responsible for the increased risk of type 2 diabetes seen with statin treatment.

  • European Medicines Agency to review Ebola therapies Subscription

    30 SEP 2014 17:50

    Experimental Ebola treatments are to be reviewed by the European Medicines Agency as part of the international response to the disease outbreak in West Africa.

  • Aptivus contraindication Subscription

    29 SEP 2014 10:01

    The summary of product characteristics for Aptivus (tipranavir; Boehringer Ingelheim) now states that co-administration of colchicine with Aptivus and ritonivir is contraindicated in patients with renal or hepatic impairment. Additionally, in patients with normal renal and hepatic function, a reduction in colchicine dosage or an interruption of colchicine treatment is recommended in co-administration. Further interaction information has also been added to the summary of product characteristics.

  • New indication for Ozurdex Subscription

    29 SEP 2014 9:59

    Ozurdex (dexamethasone; Allergan) is now indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy. Further changes to the summary of product characteristics reflect this change.

  • Dose information for Adcetris Subscription

    29 SEP 2014 9:57

    The summary of product characteristics for Adcetris (brentuximab vedotin; Takeda) now states that the recommended starting dose in patients with hepatic impairment or severe renal impairment is 1.2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks. These patients should be closely monitored for adverse events.

  • Storage conditions for Tanatril Subscription

    29 SEP 2014 9:55

    The summary of product characteristics for Tanatril (imidapril hydrochloride; Chiesi) now states that the PVC aluminium blister packs should not be stored above 25°C.

  • New indication for Spiriva Respimat Subscription

    29 SEP 2014 9:53

    Spiriva Respimat (tiotropium bromide monohydrate; Boehringer Ingelheim) is now indicated as an add-on maintenance treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids and long-acting β2 agonists and who experienced one or more severe exacerbations in the previous year. Further changes to the summary of product characteristics reflect this addition.

  • Nimenrix stability correction Subscription

    29 SEP 2014 9:47

    A correction has been made to the summary of product characteristics for Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine; GlaxoSmithKline). The drug is only stable for 8 hours after reconstitution, not 24 hours as was previously stated.

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.